[Coagulation and fibrinolytic system in the vascular risks diabetes mellitus and hyperlipoproteinemia (author's transl)].
42 patients with minifest diabetes mellitus and 42 patients with primary hyperlipoproteinemia type II, IV or V (Fredickson) underwent analysis of cholesterol, triglycerides and agar-agarosegel-lipoprotein electrophoresis. Simultaneously clotting factors I--XIII, platelet count and aggregability, fibrinolytic activity and antithrombins were determined. The most accentuated disturbances were seen in hyperlipoproteinemia type II and in diabetes mellitus comprising increase of fibrinogen content, platelet reduction and enhanced platelet aggregability, hypofibrinolysis. Only minor differences of certain clotting factors could be detected comparing diabetes mellitus and hyperlipoproteinemia type II. Diabetes mellitus being complicated by micro- or macroangiopathia revealed additional significant alterations such as more pronounced increase of fibrinogen, further platelet reduction and aggregability. Increase of fibrinogen, platelt disturbances, hypofibrinolysis and alterations of antithrombin activity in connection with metabolic diseases may be regarded as additional risk to vascular complications.
D000328:Adult; D000368:Aged; D000991:Antithrombins / Q000032:analysis; D001777:Blood Coagulation; D002784:Cholesterol / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood*; D003925:Diabetic Angiopathies / Q000097:blood; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D012306:Risk; D013921:Thrombocytopenia / Q000209:etiology; D014280:Triglycerides / Q000097:blood
D000991:Antithrombins; D014280:Triglycerides; D005340:Fibrinogen; D002784:Cholesterol
Gerinnungs- und Fibrinolysesystem bei den vaskulären Risikofaktoren Diabetes mellitus und Hyperlipoproteinämie.